Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors too optimistic about ASX growth story
stocks
Stellar growth from ASX retailer but markets still too optimistic
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,103.10 | 47.20 | -0.52% |
| CAC 40 | 7,802.49 | 49.07 | 0.63% |
| DAX 40 | 24,176.14 | 151.36 | 0.63% |
| Dow JONES (US) | 44,706.84 | 248.23 | 0.56% |
| FTSE 100 | 9,154.99 | 7.18 | 0.08% |
| HKSE | 25,613.67 | 643.99 | 2.58% |
| NASDAQ | 21,724.59 | 42.69 | 0.20% |
| Nikkei 225 | 43,274.67 | 556.50 | 1.30% |
| NZX 50 Index | 12,766.54 | 6.86 | 0.05% |
| S&P 500 | 6,456.44 | 10.68 | 0.17% |
| S&P/ASX 200 | 8,827.10 | 53.70 | -0.60% |
| SSE Composite Index | 3,683.46 | 17.55 | 0.48% |